I think many of us figure May 21st based on the submission date. We really don't know of formal acceptance though I know some people suggested a few days later. If we do have approval before ASCO it should certainly get us a great deal of attention there. I don't know that any peer reviewed submission was made for presentation there, but the Experts Theater presentation ought to get a lot of attention.
Should we not yet have a decision, I would hope the Experts Theater focuses on the development of the EDEN unit and perhaps some discussion of the compassionate use of DCVax-L in a variety of cancers in the UK.
I don't believe the filing was in any way timed to ASCO, but it would be great if it turns out that way. Remember, they originally announced the intention of filing much earlier and had two different announced delays, they certainly weren't intentional. I believe one reason approval is over 90% certain is because we've been working with the regulators all along, and such delays came about because of advice we were being given regarding what was in our filing at the time. It may have not come directly from the regulators, but remember, we contracted for much of the work in the filing. I've got to believe that our contractors also have excellent knowledge of what the regulators want.
The key is approval, how it's done may reflect on near term stock price, but will have little influence on the long term price of the stock. If NWBO isn't bought out prior to substantial revenue developing from sales, it's share price and buyout price if we get an offer will be based on revenue at the time, and forecast into the future. I was unhappy with the IMGN buyout because sufficient time hadn't occurred to understand how much revenue growth would continue to be seen. ABBV anticipated $2 billion a year, to me the $10 billion was far below what the company should have been worth.
Gary
Bullish
